RTW Biotech Opportunities Ltd (LSE: RTWG), a London-listed investment fund focused on biopharmaceutical and medical technology assets, has announced the repurchase of 158,630 ordinary shares at a price of $2.36 per share on 3 November 2026. The repurchased shares will be held in treasury and will carry no voting rights, reducing the company's total voting rights to 319,258,212. The buyback was conducted under authority granted by shareholders at the company's Annual General Meeting in June 2026, with Jefferies International Limited acting as broker for the transaction.

Key Points

  • RTW Biotech Opportunities Ltd (LSE: RTWG) is a closed-ended investment fund managed by RTW Investments, LP
  • The company repurchased 158,630 ordinary shares at $2.36 per share on 3 November 2026, to be held in treasury
  • Total voting rights now stand at 319,258,212 following settlement; 26,709,228 shares are held in treasury
  • Investors should monitor further buyback activity permitted under the existing AGM authority, which runs until the 2027 Annual General Meeting

RTW Biotech Repurchases Shares at $2.36 Under June 2026 Shareholder Authority

The company announced on 4 November 2026 that it completed the buyback of 158,630 ordinary shares on 3 November 2026 at a price of $2.36 per share. The authority for this buyback was granted by shareholders at RTW Biotech Opportunities' Annual General Meeting held in June 2026, which permits the company to repurchase a maximum of 14.99% of its ordinary shares. The announcement confirms that the actual number of shares repurchased will depend on prevailing market conditions, and the authority remains in place until a new shareholder mandate is expected to be granted at the 2027 Annual General Meeting, or until expressly revoked.

Treasury Holding and Voting Rights Following Settlement of 26,709,228 Shares

Following the purchase and settlement of these shares, RTW Biotech Opportunities' total issued ordinary share capital stands at 345,967,440 shares. Of this figure, 26,709,228 ordinary shares are now held in treasury and attract no voting rights under applicable rules. As a result, the total number of voting rights in the company is 319,258,212. The company states that this figure of 319,258,212 should be used by shareholders as the denominator when calculating whether they are required to disclose interests or changes in interests under the FCA's Disclosure and Transparency Rules.

No Premium to NAV Permitted and Jefferies International Appointed as Buyback Broker

The announcement notes that no maximum consideration payable has been determined for the buyback programme, but the company is prohibited from paying a price for any ordinary shares that would equate to a premium to net asset value. RTW Biotech Opportunities has instructed Jefferies International Limited as its broker in respect of buyback transactions, an arrangement described as being in accordance with FCA Listing Rules and the company's general repurchase authority. The company states its current intention is to hold all repurchased shares in treasury rather than cancel them.

RTW Investments, LP Manages a Healthcare-Focused Portfolio Targeting Biopharmaceutical Innovation

RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, described in the announcement as a healthcare-focused entrepreneurial investment firm with deep scientific expertise. The fund targets transformative assets across the biopharmaceutical and medical technology sectors, investing in companies developing next-generation therapies and technologies. The company operates with a long-term investment approach designed to support innovative businesses. As a closed-ended investment fund listed on the London Stock Exchange, its performance is closely tied to the valuations of its underlying portfolio holdings within the life sciences sector.